APA (7th ed.) Citation

AE, C., GE, C., PJ, R., MN, R., AW, D., RG, N., . . . JJ, E. (2026). Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study. Annals of internal medicine, 179(2), 168. https://doi.org/10.7326/ANNALS-25-01939

Chicago Style (17th ed.) Citation

AE, Colson, et al. "Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study." Annals of Internal Medicine 179, no. 2 (2026): 168. https://doi.org/10.7326/ANNALS-25-01939.

MLA (9th ed.) Citation

AE, Colson, et al. "Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study." Annals of Internal Medicine, vol. 179, no. 2, 2026, p. 168, https://doi.org/10.7326/ANNALS-25-01939.